| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,865 | -7,910 |
| Depreciation and amortization | 434 | 270 |
| Provision for inventory obsolescence | 205 | 172 |
| Loss on disposal of property and equipment | -19 | 0 |
| Stock-based compensation | 1,501 | 971 |
| Allowance for credit losses | 286 | 156 |
| Non-cash lease expense | 68 | 48 |
| Non-cash interest expense | 714 | 472 |
| Trade receivables | -2,577 | -4,413 |
| Prepaid expenses and other assets | -9 | -434 |
| Inventories | 1,585 | 720 |
| Accounts payable | 510 | 182 |
| Accrued expenses and other liabilities | -344 | -423 |
| Net cash used in operating activities | -5,471 | -1,935 |
| Purchases of property and equipment | 839 | 320 |
| Net cash used in investing activities | -839 | -320 |
| Proceeds from stock option exercises | 49 | - |
| Repayment of finance lease liabilities | 14 | 10 |
| Contributions from non-controlling interest | 60 | 60 |
| Net cash provided by (used in) financing activities | 95 | 50 |
| Effect of exchange rates on cash | -391 | -235 |
| Net change in cash and cash equivalents | -6,606 | -2,440 |
| Cash and cash equivalents at beginning of period | 31,741 | - |
| Cash and cash equivalents at end of period | 25,135 | - |
Apyx Medical Corp (APYX)
Apyx Medical Corp (APYX)